954P - A new non-chemo and non-toxic drug (24-ethyl-cholestane- 3β, 5α, 6α-triol) with antitumor activity in advanced refractory or recurrent, mainly aggr...

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Lymphomas
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Nabil Habib
Citation Annals of Oncology (2014) 25 (suppl_4): iv327-iv339. 10.1093/annonc/mdu339
Authors N.F. Habib1, H.E. Daaboul1, G. Hage1, A. Jabbour1, N. Kassem1, R. Khalifeh2
  • 1Oncology, Nabil Habib Institution, 6400 - Beirut/LB
  • 2Oncology, Nabil Habib Institution, Beirut/LB



Oxysterols are oxygenated derivatives of cholesterol. Some of these compounds may be toxic and even oncogenic while others seem promising as anticancer drugs. Advanced recurrent or refractory non-Hodgkin lymphomas (NHLs) have a dismal prognosis and are treated palliatively. (24-ethyl-cholestane- 3ß,5α,6α-triol) is an oxysterol developed by our group. Besides its high antitumor potential, it has been shown to be devoid of side-effects.


From 2001 to 2013 we have treated 14 patients (pts) suffering from relapsed or refractory non-Hodgkin lymphomas. Eight were males and 6 females. The median age was 50yrs. Eight of these pts were suffering from diffuse large B-cell lymphomas, 2 from lymphoplasmacytic lymphomas, 1 maltoma, 1 diffuse mixed, 1 anaplastic and 1 large T-cell lymphoma. Five pts were stage II (one was 2EB), 4 were stage III and 5 stage IV. Nine pts had B symptoms and 8 other symptoms (pain, neurologic symptoms, dyspnea … ). Except 2 pts, all had previously received 2 to 3 chemotherapy regimens and 5 pts had been treated with radiotherapy. Most of them had a poor performance status. Patients received daily 10 mg/kg of oral (24-ethyl-cholestane- 3ß,5α,6α-triol) divided in 3 equal doses every day, until disease progression.


Five patients exhibited a complete response (CR), 3 pts had a partial response (PR) 4 pts had a stable disease (NC) and 2 pts progressed under treatment. The median follow-up was 3 years. Most of the pts experienced a rapid (within few days) and dramatic improvement in their quality of life and fast and remarkable all-symptoms control. Some patients taking high doses of pain-killers and or opioids could stop them within 2-4 days. No side-effects of any kind were observed.


According to these excellent results, (24-ethyl-cholestane- 3ß,5α,6α-triol) seems to be a good candidate for phase II trials in NHLs with or without concurrent chemotherapies or targeted therapies.


All authors have declared no conflicts of interest.